This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

EMS not allowed to participate in Hypera-Boehringer deal review in Brazil

( April 17, 2020, 16:23 GMT | Official Statement) -- MLex Summary: Brazilian pharmaceutical giant EMS can't participate in the national competition watchdog's review of Hypera's planned buyout of Boehringer Ingelheim's antispasmodics and analgesics brands. The Administrative Council for Economic Defense said EMS filed its request after deadline, but the company will be able to comment on the transaction in its response to a questionnaire sent by the agency to EMS's controller, NC Farma.See CADE statement and document below in Portuguese....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections